Jim Cramer Discussed 10 Stocks That Can Do Well in December

3. McKesson Corporation (NYSE:MCK)

Number of Hedge Fund Holders: 57

Cramer called McKesson Corporation (NYSE:MCK) a “traditional middleman” and said:

“Ninth is McKesson, a traditional middleman between the drug companies and the drug stores. Now it’s a Trump stock, not because Trump loves the drug distributors, but because I think it was only a matter of time before the Biden-Harris regulars went after these guys. There’s a widespread belief that McKesson… got a big reprieve, rightly or wrongly.”

McKesson (NYSE:MCK) provides healthcare services, including the distribution of pharmaceuticals, medical supplies, and logistics, while offering technology, consulting, and support solutions for healthcare providers, biopharma companies, and patients. As seen in its recently reported second-quarter fiscal 2025 earnings, the company’s largest unit by revenue is the U.S. Pharmaceutical segment.

It specializes in distributing drugs for the treatment of complex conditions, such as cancer. In the second quarter, sales in this segment grew by 23% to reach $85.7 billion, driven by higher prescription volumes, specialty products, and GLP-1 medications. For the second quarter of fiscal 2025, the company reported a total revenue of $93.65 billion, which surpassed analysts’ expectations. This growth was primarily fueled by strong performance in the U.S. Pharmaceutical segment. Looking ahead, McKesson’s (NYSE:MCK) fiscal 2025 guidance anticipates a 16% to 19% increase in revenue from the U.S. Pharmaceutical segment, along with a 9% to 11% rise in operating profit.